The conference arrives at a decisive moment: after years of extensions and uncertainties, France will definitively close its medical cannabis pilot program on March 31, 2026. From April 1, 2026, a permanent pharmaceutical regime will come into force that will regulate access, pricing, distribution and prescription rights for the next decade.

Cannabis Europa Paris 2026: The Event That Matters

What Makes Cannabis Europa Paris Unique

Cannabis Europa is the leading European platform dedicated to the intersection of cannabis policy, healthcare, industry and investment. The 2026 Paris edition represents a unique opportunity for professionals, investors and policymakers to discuss the future of regulated cannabis in Europe.

The event stands out for its exclusive format: a one-day intensive conference that prioritizes quality over quantity, with curated sessions instead of generic panels. Each session is designed to provide concrete operational intelligence and actionable strategies.

Where and When

Date: Thursday, February 19, 2026

Location: Paris, France (venue: Hôtel de l’Industrie – verify on the official website for final confirmation)

Complete information: Official event page

The event will take place in the heart of Paris, ensuring easy access for international participants and creating the perfect atmosphere for high-level networking.

Strategic Partnership with UIVEC

Cannabis Europa Paris 2026 is organized in partnership with UIVEC (Union des Industriels pour la Valorisation des Extraits de Chanvre), the trade organization representing over 60 agricultural, pharmaceutical and economic stakeholders throughout the hemp extract value chain in France.

This partnership ensures that the event is deeply rooted in the realities and needs of France’s emerging cannabis industry.

Who Attends Cannabis Europa Paris

The Audience: Decision-Makers and Industry Leaders

Cannabis Europa Paris attracts a very high-level audience, composed of:

• Senior policymakers and regulators
• Healthcare leaders, clinicians and neurologists
• CEOs and executives from leading European cannabis companies
• Institutional investors, venture capital and investment banks
• Lawyers specialized in life sciences and compliance
• Pharmaceutical industry representatives
• Scientific researchers
• Commercial operators and entrepreneurs

The event is primarily B2B (business-to-business), with approximately 90% professional participants. The remaining 10% includes patients and advocacy organizations, recognizing the central role of patients in the medical cannabis ecosystem.

Important note: Cannabis Europa offers reduced-rate tickets for patients wishing to attend, recognizing that without them the event’s mission would be meaningless.

International Speakers of the Highest Caliber

The program includes some of the most influential names in the European and global cannabis sector:

Gérard Mick

Neurologist and Head of the Pain Center at Grenoble-Alpes University Hospital. He brings direct frontline clinical experience on patient access and therapeutic outcomes in the French healthcare system.

Tyler Robson

President of Cannabis at SNDL, one of North America’s most established cannabis groups. He shares global operational experience from mature markets like Canada, offering valuable comparative lessons for Europe.

Marie Sanchez

Attorney at NOOA Avocats (Paris), specialized in life sciences regulation. She analyzes the legal and compliance implications of the new French regulatory framework.

Zoé Demange

General Manager of UIVEC. She represents the interests and realities of France’s emerging medical cannabis industry, offering an insider’s perspective on the industrial ecosystem.

Mado Gilanton

President of APAISER S&C. She contributes insights from within France’s supply and patient ecosystem, ensuring that the patient voice is central to the conversation.

The Agenda: Key Conference Topics

France’s Transition: From Pilot to National Program

The heart of the event is exploring France’s transition from an experimental pilot program to a permanent national medical cannabis access system.

Delegates will gain:

• A clear understanding of France’s 2026 regulatory framework
• Practical operational implications for healthcare and industry
• Broader European signals emerging from this historic moment

The program includes:

• Opening keynotes
• Policy deep-dives
• Clinical pathway sessions
• Market development panels
• Comparisons with Canada, Luxembourg and Switzerland

The Infrastructure of Access: 5 Million Patients?

One of the key sessions addresses the crucial question: “Can Europe scale to 5 million medical cannabis patients?”

The program explores:

• Scientific evidence standards
• Prescription pathways
• Sustainable commercial frameworks
• Reimbursement models
• Pharmaceutical standards
• Domestic production

The goal is to build a sustainable, patient-centered medical cannabis market in France and throughout Europe.

Comparative Lessons from Mature Markets

Cannabis Europa Paris draws on comparative lessons from more established medical cannabis markets:

• Canada: Operational experience from one of the world’s most mature markets
• Switzerland: Innovative pilot programs and pragmatic approaches
• Luxembourg: Domestic legalization and transition to regulated systems

These international comparisons help avoid mistakes already made by other countries and accelerate the implementation of best practices.

Why France Matters in 2026

An Enormous Potential Market

France represents one of Europe’s most significant potential markets for medical cannabis:

• Population: 67 million inhabitants
• Robust and well-organized healthcare system
• Established pharmaceutical tradition
• Strategic position in Europe

The French Ministry of Health is examining long-term regulation, and the country appears ready to finally realize its potential in the coming years.

The Domino Effect of German Reform

The German reform of 2024 has reshaped investment sentiment and ignited new political momentum throughout the European Union. France is closely watching the German model and appears ready to develop its own distinctive approach.

For the global cannabis industry, long excluded from the French market, this moment is probably more consequential than German legalization itself, given the size and strategic importance of the French market.

Perfect Timing: Policy into Practice

Cannabis Europa Paris 2026 is perfectly positioned at the moment when policy transforms into practice:

• March 31, 2026: End of the five-year pilot program
• April 1, 2026: Beginning of the permanent pharmaceutical-style regime

The event offers the opportunity to:

• Build a profile in the emerging market
• Forge strategic partnerships
• Own the conversation at a crucial moment
• Understand operational implications before implementation

Tickets and Practical Information

Ticket Types

Early Bird tickets are already sold out, a sign of strong demand for this event. General Release tickets are available on a first-come, first-served basis.

Indicative pricing:

• Standard: from approximately €300
• VIP: access to VIP lounge, priority seating, concierge assistance

Important: Ticket prices increase on February 5, 2026. Booking early allows you to save over 20%.

Capacity is limited, emphasizing the exclusivity and value of the event.

How to Register

For updated information on tickets and registration, visit the official event page: cannabis-europa.com/events/cannabis-europa-paris-2026/

Networking Excellence

Beyond the Sessions: The Value of Networking

Networking at Cannabis Europa Paris is exceptional. The intimate setting and caliber of attendees ensure meaningful conversations rather than simple business card exchanges.

Evening events in iconic Parisian venues extend networking into settings befitting the city’s reputation, offering opportunities to:

• Deepen professional relationships
• Discuss opportunities in informal contexts
• Close deals in a relaxed atmosphere

For executives seeking entry or expansion into the European market, this is essential intelligence-gathering.

Cannabis Europa: The Reference Platform

Mission and Values

Cannabis Europa is committed to:

• Access: Improving patient access to safe and effective cannabis medicines
• Education: Providing clear, evidence-based knowledge about medicinal cannabis
• Innovation: Encouraging research and investment that unlocks new applications
• Impact: Recognizing cannabis as a force for positive change
• Collaboration: Bringing together voices from policy, science, investment and industry

Global Reach

With participants from over 40 countries, Cannabis Europa has a truly international reach. The events drive the dialogue that informs regulation, attracts capital and sets the agenda for Europe’s legal industry.

What Follows: Cannabis Europa London 2026

After Paris, Cannabis Europa will return to London for a two-day conference and expo on May 26-27, 2026, continuing the dialogue shaping Europe’s regulated cannabis future.

The London event:

• Location: Barbican Centre
• Attendees: approximately 1,500
• Speakers: over 70
• Exhibitors: over 50

The London event will also include the Business of Cannabis Awards ceremony on the evening of May 26, 2026.

Why Attend Cannabis Europa Paris 2026

For Investors and Venture Capital

• Identify investment opportunities in an emerging market
• Meet startups and established companies
• Understand the regulatory framework for informed valuations

For Cannabis Operators and Entrepreneurs

• Explore strategies for entering the French market
• Build commercial partnerships
• Learn from mature markets

For Policymakers and Regulators

• Exchange with European colleagues
• Learn from international experiences
• Contribute to the regulation debate

For Healthcare Professionals and Researchers

• Update on scientific evidence
• Understand prescription pathways
• Exchange with international colleagues

For Service Providers (Legal, Consulting, Tech)

• Expand client network
• Understand compliance needs
• Offer specialized solutions

The European Medical Cannabis Context in 2026

Germany: The Reference Model

With the legalization of April 2024 and Cannabis Social Clubs, Germany represents the largest European cannabis market. Medical sales are expected to reach €420 million in 2024 and exceed €1 billion by 2028.

Malta: The Recreational Pioneer

First EU country to fully legalize recreational cannabis in December 2021.

Luxembourg: Domestic Legalization

Since July 2023, allows home cultivation and private consumption.

Czech Republic: 2026 Novelty

As of January 1, 2026, introduces one of Europe’s most progressive regulatory frameworks.

A Moment Not to Be Missed

Cannabis Europa Paris 2026 is not just a conference: it is the meeting point between the past and future of European medical cannabis. It is where policy meets business opportunity, where ideas become influence and where capital identifies opportunities.

For those operating in the European cannabis sector or considering entering it, February 19, 2026 in Paris is a date to mark on the calendar. It is where the future of French and European medical cannabis takes concrete shape.

Cannabis Europa website: cannabis-europa.com